Cloudbreak Pharma Inc
02592
Company Profile
Business description
Cloudbreak Pharma Inc is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to the development of novel and differentiated treatments. The company’s focus is on Meibomian Gland Dysfunction Associated Dry Eye Disease, Pterygium, Pinguecula, Glaucoma Filtration Surgery, Wet Age-Related Macular Degeneration, and Myopia Progression. Its drugs in pipeline include CBT-001, CBT-004, CBT-006, CBT-007, CBT-009, and CBT-011.
Contact
8921 Research Drive
IrvineCA92618
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,120.90 | 8.50 | -0.09% |
| CAC 40 | 7,674.78 | 24.14 | -0.31% |
| DAX 40 | 23,596.98 | 173.35 | -0.73% |
| Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
| FTSE 100 | 9,208.21 | 8.66 | -0.09% |
| HKSE | 25,417.98 | 359.47 | 1.43% |
| NASDAQ | 21,700.39 | 7.30 | -0.03% |
| Nikkei 225 | 43,789.16 | 770.41 | 1.79% |
| NZX 50 Index | 13,235.40 | 11.87 | 0.09% |
| S&P 500 | 6,481.50 | 20.58 | -0.32% |
| S&P/ASX 200 | 8,847.60 | 7.60 | -0.09% |
| SSE Composite Index | 3,812.51 | 46.64 | 1.24% |